К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

RECIST 1.1 on a CT report: how tumor response to treatment is rated

RECIST 1.1 is the rulebook radiologists use to measure lesions and rate response: complete, partial, stable or progression. What the 30% and 20% cut-offs mean.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

RECIST 1.1 is an international set of criteria for rating how a solid tumor responds to treatment, based on lesion size on CT or MRI. It turns “the tumor seems smaller” into one of four categories with clear cut-offs.

How it appears in your report

  • “Target lesions: 1) … mm, 2) … mm; sum of diameters … mm (baseline … mm)”.
  • “Non-target lesions: no significant change”.
  • “No new lesions”.
  • “RECIST 1.1 response: partial response (PR)” — sometimes just CR, PR, SD or PD.

Target lesions are measurable lesions tracked by the sum of their diameters. Non-target lesions are all the others; they are described but not measured.

What it means

The main RECIST 1.1 rules:

  • up to 5 target lesions, no more than 2 per organ;
  • a lesion is measurable if its longest diameter is at least 10 mm on CT with a slice thickness of 5 mm or less;
  • a lymph node can be a target if its short axis is 15 mm or more; a node under 10 mm on the short axis is considered normal.
Category Criterion
Complete response (CR) All lesions gone, lymph nodes under 10 mm on the short axis
Partial response (PR) Sum of diameters down by at least 30% from baseline
Progression (PD) Sum up by at least 20% from the smallest sum on treatment and by at least 5 mm, or a new lesion
Stable disease (SD) Neither PR nor PD

One important detail: shrinkage is measured from baseline, growth from the smallest sum. If a tumor first shrank a lot and then grew a little, that can already count as progression even though it is still smaller than before treatment.

Does it affect treatment

The response category is the main argument in deciding whether to continue the current treatment. But your oncologist also weighs how you feel, tumor markers and other tests. With immunotherapy a modified version, iRECIST, is used because of pseudoprogression. The decision is made by your treating doctor or a tumor board. If your report says PD and you want the conclusion checked, I can review your scans and records as a second opinion.

Questions to ask your doctor

  • Which scan was this compared with, and which lesions were chosen as targets?
  • Is this a formal RECIST assessment or a descriptive one?
  • If the change is borderline, when is the next scan?

Sources

  1. RECIST 1.1 — RECIST Working Group / EORTC; Eisenhauer E.A. et al., European Journal of Cancer, 2009
  2. Response evaluation criteria in solid tumours (RECIST) — Radiopaedia
  3. iRECIST guidelines — RECIST Working Group / EORTC, 2017

Watch me explain this on video

Short videos on my Instagram (in Russian)

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles